Alterations of calcium homoeostasis in cultured rat astrocytes evoked by bioactive sphingolipids.

AIM: In the brain, alterations in sphingolipid metabolism contribute to several neurological disorders; however, their effect on astrocytes is largely unknown. Here, we identified bioactive sphingolipids that affect intracellular free calcium concentration ([Ca(2+)]i), mobility of peptidergic secretory vesicles, signalling pathways involved in alterations of calcium homoeostasis and explored the relationship between the stimulus-evoked increase in [Ca(2+)]i and attenuation of vesicle mobility. METHODS: Confocal time-lapse images were acquired to explore [Ca(2+)]i signals, the mobility of fluorescently tagged peptidergic vesicles and the structural integrity of the microtubules and actin filaments before and after the addition of exogenous sphingolipids to astrocytes. RESULTS: Fingolimod (FTY720), a recently introduced therapeutic for multiple sclerosis, and sphingosine, a releasable constituent of membrane sphingolipids, evoked long-lasting increases in [Ca(2+)]i in the presence and absence of extracellular Ca(2+); the evoked responses were diminished in the absence of extracellular Ca(2+). Activation of phospholipase C and inositol-1,4,5-triphosphate receptors was necessary and sufficient to evoke increases in [Ca(2+)]i as revealed by the pharmacologic inhibitors; Ca(2+) flux from the extracellular space intensified these responses several fold. The lipid-evoked increases in [Ca(2+)]i coincided with the attenuated vesicle mobility. High and positive correlation between increase in [Ca(2+)]i and decrease in peptidergic vesicle mobility was confirmed independently in astrocytes exposed to evoked, transient Ca(2+) signalling triggered by purinergic and glutamatergic stimulation. CONCLUSION: Exogenously added cell-permeable sphingosine-like lipids exert complex, Ca(2+)-dependent effects on astrocytes and likely alter their homeostatic function in vivo.

Amyotrophic lateral sclerosis immunoglobulins G enhance the mobility of Lysotracker-labelled vesicles in cultured rat astrocytes.

AIM: We examined the effect of purified immunoglobulins G (IgG) from patients with amyotrophic lateral sclerosis (ALS) on the mobility and exocytotic release from Lysotracker-stained vesicles in cultured rat astrocytes. METHODS: Time-lapse confocal images were acquired, and vesicle mobility was analysed before and after the application of ALS IgG. The vesicle counts were obtained to assess cargo exocytosis from stained organelles. RESULTS: At rest, when mobility was monitored for 2 min in bath with Ca(2+), two vesicle populations were discovered: (1) non-mobile vesicles (6.1%) with total track length (TL) < 1 µm, averaging at 0.33 ± 0.01 µm (n = 1305) and (2) mobile vesicles (93.9%) with TL > 1 µm, averaging at 3.03 ± 0.01 µm (n = 20,200). ALS IgG (0.1 mg mL(-1)) from 12 of 13 patients increased the TL of mobile vesicles by approx. 24% and maximal displacement (MD) by approx. 26% within 4 min, while the IgG from control group did not alter the vesicle mobility. The mobility enhancement by ALS IgG was reduced in extracellular solution devoid of Ca(2+), indicating that ALS IgG vesicle mobility enhancement involves changes in Ca(2+) homeostasis. To examine whether enhanced mobility relates to elevated Ca(2+) activity, cells were stimulated by 1 mm ATP, a cytosolic Ca(2+) increasing agent, in the presence (2 mm) and in the absence of extracellular Ca(2+). ATP stimulation triggered an increase in TL by approx. 7% and 12% and a decrease in MD by approx. 11% and 1%, within 4 min respectively. Interestingly, none of the stimuli triggered the release of vesicle cargo. CONCLUSION: Amyotrophic lateral sclerosis-IgG-enhanced vesicle mobility in astrocytes engages changes in calcium homeostasis.